Recently, convalescent plasma (CP) transfusion was employed for severe or critically ill patients with coronavirus disease-2019. However, the benefits of CP for patients with different conditions are still in debate. To contribute clinical evidence of CP on critically ill patients, we analyze the characteristics and outcomes of patients with or without CP transfusion. In this cohort study, 14 patients received CP transfusion based on the standard treatments, whereas the other 10 patients received standard treatments as control. Clinical characteristics and outcomes were analyzed. The cumulative survival rate was calculated by Kaplan–Meier survival analysis. Data analysis was performed on 24 patients (male/female: 15/9) with a median age of 64.0 (44.5–74.5) years. Transient fever was reported in one patient. The cumulative mortality was 21% (3/14) in patients receiving CP transfusion during a 28-day observation, whereas one dead case (1/10) was reported in the control group. No significant difference was detected between groups in 28-day mortality (P = 0.615) and radiological alleviation of lung lesions (P = 0.085). In our current study, CP transfusion was clinically safe based on the safety profile; however, the clinical benefit was not significant in critically ill patients with more comorbidities at the late stage of disease during a 28-day observation.

中文翻译：

---

2019 年冠状病毒病危重患者的恢复期血浆临床获益有限：一项队列研究

最近，恢复期血浆 (CP) 输注被用于重症或危重症患者的冠状病毒病 - 2019。然而，CP 对不同疾病患者的益处仍存在争议。为了提供重症患者 CP 的临床证据，我们分析了有或没有 CP 输血的患者的特征和结果。在该队列研究中，14 名患者接受了基于标准治疗的 CP 输血，而其他 10 名患者接受了标准治疗作为对照。分析了临床特征和结果。通过 Kaplan-Meier 生存分析计算累积生存率。对 24 名中位年龄为 64.0 (44.5-74.5) 岁的患者（男性/女性：15/9）进行了数据分析。一名患者报告了一过性发热。在 28 天观察期间接受 CP 输注的患者的累积死亡率为 21% (3/14)，而对照组报告了 1 例死亡病例 (1/10)。在 28 天死亡率 (P = 0.615) 和肺部病变的放射学缓解 (P = 0.085) 方面，各组之间未检测到显着差异。在我们目前的研究中，基于安全性特征，CP 输血在临床上是安全的；然而，在 28 天的观察期间，在疾病晚期合并症较多的危重患者中，临床获益并不显着。根据安全性特征，CP 输血在临床上是安全的；然而，在 28 天的观察期间，在疾病晚期合并症较多的危重患者中，临床获益并不显着。根据安全性特征，CP 输血在临床上是安全的；然而，在 28 天的观察期间，在疾病晚期合并症较多的危重患者中，临床获益并不显着。